Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-lactam dosing scheme validation in septic hemodialysis patients
2015-001809-14Phase 4Completed
- Sponsor
- Erasmus Hospital
- Start
- May 2015
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ceftazidime, piperacillin + tazobactam and meropenem in sepsis (3 arms), sponsored by Erasmus Hospital. Primary endpoints: Pharmacokinetics of ceftazidime, Pharmacokinetics of piperacillin + tazobactam and 1 more. Started May 2015; status: completed.
02
Drugs
ceftazidimepiperacillin + tazobactammeropenem
03
Conditions
sepsis
Beyond the preview
Go deeper on 2015-001809-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001809-14.